Background Clinical practice guidelines (CPG) endorse multiple strategies to prevent or manage preterm birth (PTB).
Introduction
Complications from preterm births (PTB) are a primary cause of neonatal deaths worldwide, with surviving infants at risk of serious neonatal complications and long-term disability. 1 The economic cost of PTB was estimated to be £2.9 billion for a single year in the UK, 2, 3 with the psychological, social and financial costs to families no less profound. 4, 5 A World Health Organization (WHO) priority-setting exercise identified PTB as a 'top ten' research priority to 2025. 6 Discovery research to prevent PTB is also a key component of the global strategy to reduce newborn deaths, as set out in the United Nations' Sustainable Development Goals to 2030. 7 Experts continue to debate the optimal clinical care of pregnant women to prevent or manage PTB. Short-and long-term effects of diverse interventions must be set against women's individual histories and preferences. Clinical setting also has an important impact on cost-effectiveness. Even within the diverse individual, social and economic structures that shape women's antenatal care, it is now accepted that healthcare providers can improve outcomes for pregnant women and their babies by following evidence-based guidelines. 8, 9 There is also widespread agreement that use of guidelines can improve efficient use of resources, 10 but implementation remains difficult.
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A recent study suggests that methods for guideline development have improved. 12 As the need for up-to-date guidance continues, efforts to reduce duplication, improve collaboration among guideline developers and establish methods for guideline adaptation and more efficient updating have received wider consideration. 13, 14 The objectives of this study are to propose a methodology for reviewing the content of practice guidelines and, with this, to identify consensus and inconsistency in recommendations across the PTB-related guidelines.
Methods
We based our review methods on two systematic reviews of guidelines. 8, 9 Search strategy
In June 2016 we searched six online databases including Medline (Ovid) using a broad search strategy without language restrictions. We checked references for additional guidelines and hand-searched the websites of professional societies. In May 2017 we repeated our hand searches and the Medline (Ovid) search, and we searched the online database Literatura Latino Americana en Ciências da Sa ude virtual health library (LILACS). All search strategies combined the keywords preterm or premature with birth, labour or delivery. Where possible, we limited the search results of online databases to the article type 'practice guideline'. Full details of individual database search terms and results appear in Supporting Information Appendix S1 and in a published protocol for this review. 15 We developed a list of clinical questions to inform the eligibility of practice guidelines and enable efficient searches of guidelines. The list emerged from the Cochrane Pregnancy and Childbirth review topic list and close readings of widely known practice guidelines; the process was iterative. The finalised list of 27 clinical questions delineates the scope of this review (Table 1) . We did not search for or summarise topics relevant to PTB beyond those prespecified in our clinical questions. Eligible guidelines met the following criteria:
The guideline was published or assessed as current from June 2013. The guideline recommended clinical practices for the prevention or management of PTB relevant to our prespecified questions on screening, medications or surgery and other interventions. Guidelines targeted asymptomatic pregnant women, women with risk factors or women presenting with clinical signs of preterm labour or birth as defined by the guideline. Women had singleton or multiple pregnancy. Guidelines were written for single or multiple interventions. Publications on the methodology of guideline development for eligible CPG were included to enable quality assessment. Two researchers completed eligibility assessment independently; we resolved conflicts through discussion. We sought help from native speakers with clinical expertise to assess the eligibility of several guidelines not published in English, as documented below in Acknowledgements. We did not carry out duplicate assessment of foreign language guidelines.
Quality assessment
We assessed the adherence of guidelines to four of 13 Institute of Medicine (IOM) Standards for a Trustworthy Guideline. 16, 17 We chose four general standards prioritised by this review team:
Did the guideline describe a development and funding process that was publicly accessible? Did the guideline address gaps in evidence and summarised evidence for benefits and harms related to each recommendation? Was the guideline based on a systematic review of available evidence? Was the guideline developed by a multidisciplinary panel made up of clinical experts and patients or other health consumers? Most included guideline developers contributed more than one guideline to this review. Therefore, we summarised adherence to IOM standards for each included guideline developer (based on methodological papers and select guidelines) rather than for each of the 49 included guidelines. We conducted duplicate quality assessment with disagreement resolved by discussion.
Summarising evidence
To summarise guideline recommendations we divided the clinical questions into screening strategies, medications and surgical or other interventions. Two authors independently categorised recommendations according to the following scheme:
Yes -the guideline recommends the practice Conditional yes -the guideline recommends the practice for specific subgroups of women Consider -the guideline states that the practice may be considered under certain conditions or in subgroups No -the guideline advises against the practice The guideline states further research is needed or there is insufficient evidence to recommend The guideline does not mention the clinical question The guideline recommendation is unclear For each clinical question we then reported the number of guidelines with relevant recommendations and used this number as a 'denominator'. When a guideline's recommendation for a specific clinical question was classified as 'Yes' or 'Conditional yes' for more than 70% of guidelines reporting on the question, we understood this as general support between guidelines and overall endorsement. This logic also applied to recommendations against using an intervention to prevent or treat PTB. If more than 70% of reporting guidelines recommend that a clinical strategy not be used with 'No' or 'Not enough evidence'' we recorded this as consensus on not using the intervention. We did not summarise guideline recommendations for health providers to 'consider' various treatments, nor did we summarise unclear recommendations. We note specific clinical questions with no or very few guideline recommendations in the discussion below.
Results
Of 750 screened records, 639 were excluded as being irrelevant or duplications and 55 were not practice guidelines or were published before 2013. We included 56 articles (49 guidelines 18, 19 Included practice guidelines and reports on guideline methods are listed in the references to this paper. We documented search results and eligibility decisions in Supporting Information Figure S1 (PRISMA flow diagram) and Supporting Information Appendix S2 (Excluded studies).
Sixteen of the 49 included guidelines were written specifically for the prevention or management of PTB. Other guidelines covered the following topics: obstetric, antenatal or perinatal care (6); prelabour rupture of membranes (PROM) or preterm prelabour rupture of membranes (PPROM) (5); ultrasound in pregnancy (4); magnesium sulphate (4); multiple or twin pregnancy (3) ; screening during pregnancy (3); and cerclage (2) . Single guidelines addressed antibiotics during pregnancy, nifedipine, tocolysis and progesterone.
We assessed development methodologies for adherence to four of 13 IOM indicators of quality. 22, 23 See Supporting Information Table S1 for complete assessments.
Seven guideline developers had clear and publicly accessible funding processes. Four additional developers replied via email to describe their funding process (ACOG; China; SOGC; SA). Remaining guideline developers provided no clear information regarding funding attached to publications or websites.
All guideline developers made efforts to assess gaps in evidence and consider both benefits and harmful effects related to recommendations. Guideline developers based recommendations on formal systematic reviews of evidence, with the exception of two: both Michigan and The Royal Women's Hospital Australia drew evidence from literature searches (which included Cochrane systematic reviews). 69, 70, 72 Finally, nine guideline developers included patients or members of the public in interdisciplinary guideline panels. Two guideline developers reported (via email) that they involved no members of the public or patients [China; SOGC]; remaining guidelines had no details.
The quality assessment validates our eligibility decisions. Included guidelines were overwhelmingly based on goodquality methods, including systematic reviews of available evidence and the consideration of harms as well as benefits of interventions. Just under half of the included guidelines made their funding process publicly available. More than half of the included guideline developers involved patients or members of the public.
Recommendations for clinical practice
We summarised recommendations for clinical practice in Tables 2-4 and Supporting Information Tables S3-S5 ).
Where we identified conditional recommendations, we included the parameters in footnotes. All recommendations extracted for all included guidelines can be found in Table S2A -C.
Five of our clinical questions related to screening practices (Table 2) . We found consensus for two clinical scenarios. Guidelines reporting on cervical length (CL) screening for highrisk women endorsed the practice for this subgroup. No guideline advised against using CL screening in high-risk women. Just two guidelines reported on screening for asymptomatic bacteriuria to prevent PTB; both recommended this strategy.
Most guidelines advised against using universal screening of CL in each pregnancy; just two of the eight guidelines that reported recommendations for this practice endorsed universal screening (Michigan; Japan). A similar number of guidelines advised against screening for bacterial vaginosis (BV) in pregnant women without signs of preterm labour or PPROM. Two guidelines argued for BV screening for women with a history of PTB or risk factors (Queensland; SOGC). Guidelines disagreed on the appropriate use of fibronectin, with four guidelines endorsing its use in specific circumstances and three advising against.
Ten clinical questions related to the use of medications to prevent or manage PTB (Tables 3 and S3) . Guidelines endorsed using active strategies for five of these: short-term tocolysis; magnesium sulphate for fetal neuroprotection; antibiotics for women with PPROM; vaginal progesterone for women without symptoms or history of PTB but with an evident short cervix before 24 weeks' gestation; and steroids for women with threatened PTB.
Guidelines advised against using the following: antibiotic prophylaxis for women with intact membranes but threatened PTB, longer term tocolysis to prolong gestation and vaginal progesterone for women with twin pregnancy.
For two clinical questions we found recommendations both for and against with no overall consensus. Guidelines were divided on whether or not to use vaginal progesterone in women with prior PTB but without short cervix. Ten guidelines reported recommendations on the use of a second dose of steroids for women who continue to be at risk of PTB; five guidelines endorsed a second dose and five did not.
Twelve clinical questions covered various surgical strategies to prevent or manage PTB (Tables 4 and S4 ). We found consensus for three questions. All guidelines reporting on cerclage agreed the procedure should be performed for women with short cervix and a previous PTB. Likewise, guidelines supported elective cerclage for women with multiple prior losses. Two guidelines also endorsed transabdominal cerclage after failed cervical cerclage. No other circumstances warranted cerclage. Guidelines advised against cerclage for women with short cervix but without prior PTB. Cerclage was not recommended for women with a single prior loss. Guidelines advised against using cerclage for women with twin pregnancy and for women with uterine anomalies or cervical surgery as the sole indication. Guidelines advised against using cervical pessary for women with singleton or multiple pregnancy; likewise, guidelines advised against combining progesterone with cervical cerclage. There was very little guidance for two clinical questions: no included guideline addressed amnioinfusion in preterm prelabour rupture of membranes and just two guidelines stated that there was insufficient evidence to make a recommendation for the use of rescue or emergency cerclage.
Discussion

Main findings
This review of PTB-related guidelines aimed to identify areas of international consensus as well as contested or under-studied clinical strategies. We identified nine recommendations with consensus regarding the benefit for PTB: CL screening for high-risk women; screening for asymptomatic bacteriuria; vaginal progesterone for women with a short cervix before 24 weeks' gestation; short-term tocolysis for women at risk of PTB; antibiotics for women with PPROM; magnesium sulphate for fetal neuroprotection; and steroids for women at risk of PTB. Guidelines also endorsed cerclage for women with multiple prior losses and for women with prior PTB and a short cervix before 24 weeks' gestation. Further, we found 12 interventions deemed ineffective which should not be supported, including antibiotics for women with intact membranes and signs of PTB, universal CL screening, and cerclage in women with a single prior loss, multiple pregnancy or no history of PTB. We found no intervention endorsed to prevent or manage PTB in multiple pregnancy. Importantly, for several clinical questions we found contradictory recommendations -on the use of fibronectin, vaginal progesterone and a second dose of steroids for women with continued risk of PTB. Recommendations for these clinical questions deserve further scrutiny. Finally, we found few or no guideline recommendations for cervical pessary, for amnioinfusion for women with ruptured membranes or for emergency cerclage -these topics deserve further study.
Strengths and limitations
Strengths of this project include the comprehensiveness of searches (without language restrictions) and quality assessment to confirm that we summarised the most relevant, publicly available practice recommendations. In addition we proposed methodology for guideline review to encourage research collaboration and reduce waste by identifying areas of international consensus.
We based the scope of our review on prespecified clinical questions and followed transparent, replicable methods to reduce bias. Though we considered the Cochrane Pregnancy & Childbirth topic list and well-known pregnancy guidelines to prioritise 27 clinical questions, our review of PTB guidance is not exhaustive. Other author teams may have approached guidelines with different priorities. For example, peer reviewers of our paper felt strongly that we should have included diagnostic accuracy of tests for preterm labour and the role of low-dose aspirin among our clinical questions. We chose not to deviate from the clinical questions described in our published protocol, but this criticism highlights the importance of a transparent method to determine the scope of a review. For topics as wide-ranging as PTB prevention and treatment, review teams may require significant input from a broad range of stakeholders to prioritise a clinical topic list and, thereby, enable the structured review of guidelines. Another criticism was related to our failure to comply with the CROWN initiative and use the PTB core outcome set (COS) to structure data synthesis. 76 The methodology proposed here summarises guideline recommendations for interventions rather than for specific outcomes. However, there is no question that adherence of trials to COS domains would improve the quality of guidelines by strengthening the evidence base for key interventions. Adoption of COS domains may also improve consistency of guideline recommendations.
There are several additional limitations to our synthesis. Ambiguous wording obstructs the implementation of guideline recommendations. 14 We took the view that guideline recommendations to 'consider' various treatments were too vague to classify. We chose not to evaluate the feasibility of recommendations in different settings or to search for relevant cost-effectiveness data or implementation strategies. We also did not summarise guidelines' ratings of the quality of evidence supporting recommendations.
Interpretation in light of other evidence
To inform World Health Organization (WHO) guideline development, in 2016, Abalos et al. 8 and Miller et al. 9 systematically reviewed CPG recommendations for antenatal care and routine maternity care. Both reviews noted discrepant recommendations. Miller et al. 9 also used AGREE II scores to select higher-quality guidelines for further analysis; they compared CPG recommendations to clinical practice using coverage rates for several recommended and not recommended interventions. Neither WHO review evaluated the quality of the evidence supporting recommendations. Other systematic reviews of CPG for hypertension, sugar intake and antenatal infection screening reported similar methods [77] [78] [79] . However, no review listed clinical questions a priori as we have done. Our proposed methodology renders the scope of the review transparent and reproducible, enables efficient searching of CPG and, importantly, eliminates post hoc or informal prioritisation of clinical questions.
For clinical areas such as PTB prevention and management, where multiple clinical practice guidelines exist, funders should promote collaboration among guideline developers and encourage the adaptation of existing goodquality guidelines to suit local requirements. 13, 14 To facilitate this process, we urge funders and future guideline developers to conduct a systematic review of all relevant clinical practice guidelines before embarking on new, resource-intense guideline development projects.
Conclusion
Effective strategies to avoid preterm birth are crucial for reducing newborn deaths worldwide. For clinical practice guidelines to improve health outcomes for women and babies, guidelines must present clear, credible and feasible recommendations. To avoid waste of scarce resources, we propose a method for systematic reviews of guidelines as a prudent first step in the development of practice guidelines. We welcome suggestions for improvement of these methods. Researchers should also consider systematic reviews of guidelines as a strategy to identify research priorities and to improve efficiency and collaboration among guideline developers. 
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